Development of a selectively AURKB targeting peptide degradation drug with artificial intelligence-assisted design for the treatment of acute lymphoblastic leukemia
Our findings demonstrate that ATPD is the first AI-designed, selective AURKB degrader with potent anti-leukemic activity. This study highlights ATPD's potential as a novel, precise therapeutic strategy for the treatment of ALL, addressing a critical gap in managing refractory and relapsed disease.
Authors
- Hui Feng (ORCID: https://orcid.org/0000-0003-1318-821X)
- F. Niu (ORCID: https://orcid.org/0000-0002-4621-9337)
- Yinong Huang (ORCID: https://orcid.org/0000-0002-7364-2894)
- Bingyu Yang (ORCID: https://orcid.org/0000-0003-4096-5707)
- Runyu Yang (ORCID: https://orcid.org/0000-0002-3669-4249)
- Yun Xie
- Hong Lei (ORCID: https://orcid.org/0000-0002-6242-0129)
- Bohan Ma (ORCID: https://orcid.org/0009-0001-5656-8020)
- Wei He (ORCID: https://orcid.org/0000-0003-4578-6652)
Institutions
- Northwest Women's and Children's Hospital (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Xi’an Children’s Hospital (CN)
Publication Details
- Journal
- Journal of Advanced Research
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.jare.2025.10.061
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00